Insulin Detemir

Evidence Level: L5 Predicted Indications: 2

Quick Overview

Item Value
Drug Name Insulin Detemir
DrugBank ID DB01307
Brand Names (EU) Levemir
Evidence Level L5
Predicted Indications 2
Top Prediction Score 50.00%

Approved Indication (EMA)

Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Predicted New Indications

TxGNN model predictions for potential drug repurposing:

Rank Indication Score Source
1 diabetic ketoacidosis 50.00% KG
2 diabetes mellitus (disease) 50.00% KG

About TxGNN Predictions

Prediction Sources

Source Description
KG Knowledge Graph - Network topology-based associations
DL Deep Learning - Neural network score prediction

Evidence Levels

Level Definition
L1 Multiple Phase 3 RCTs / Systematic Reviews
L2 Single RCT or multiple Phase 2 trials
L3 Observational studies / Large case series
L4 Preclinical / Mechanistic / Case reports
L5 AI prediction only (current)

Clinical Validation Needed

Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.

Next Steps for Validation

  1. Literature Review: Search PubMed for existing evidence
  2. Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
  3. Mechanistic Analysis: Evaluate biological plausibility
  4. Preclinical Studies: Conduct in vitro/in vivo validation
  5. Clinical Trials: Design and conduct human studies

Data Access

Citation

If using this data, please cite:

@article{huang2023txgnn,
  title={A foundation model for clinician-centered drug repurposing},
  author={Huang, Kexin and others},
  journal={Nature Medicine},
  year={2023},
  doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.